We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Overall, in the network meta-analysis, prasugrel reduced MACE, MI, and stent thrombosis with no increase in major bleeding compared with clopidogrel. Ticagrelor reduced stent thrombosis, but increased major bleeding, intracranial hemorrhage, and drug discontinuation due to adverse events compared with clopidogrel. Finally, prasugrel reduced MACE, MI, and stent thrombosis with no increase in major bleeding compared with ticagrelor. Thus, prasugrel provided the optimal balance between efficacy and safety.”
No takes yet. Share an insight, caveat, or question.
Yuji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: